CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05927857
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:58.708736+00:00
Published At: 2026-04-09T00:00:00+00:00
Record Updated At: 2026-04-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Gastric Adenocarcinoma", "Second Line", "Chemotherapy"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-09"
protocolSection.identificationModule.nctId: "NCT05927857"
protocolSection.identificationModule.officialTitle: "A Phase Ib/II Study of Ramucirumab (Cyramza\u00ae), Nal-IRI (ONIVYDE\u00ae) and Trifluridine/Tipiracil (Lonsurf\u00ae) in Second Line Metastatic Gastric Cancer (COOL Study)."
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.